Conexeu Sciences Inc.

S-1/A amended

S-1/A amended

Conexeu Sciences Inc. filed an S-1/A amendment (Amendment No. 4) to register the resale of up to 9,481,123 shares of common stock by registered securityholders. The shares include those from a debt settlement, private placements, business advisory agreements, Regulation Crowdfunding, and warrants. The filing outlines the company's direct listing on Nasdaq under the symbol 'CNXU,' with details on the price validation process and the role of its financial advisor. The company does not receive proceeds from resale but may benefit from warrant exercises. The prospectus highlights risks related to the lack of a public market, limited trading history, and volatility associated with a direct listing.

S-1/A amended

Conexeu Sciences Inc. is registering the resale of up to 9,481,123 shares of common stock issued under various agreements, including debt settlements, private placements, and crowdfunding offerings. The company is seeking Nasdaq listing under the symbol 'CNXU' and outlines a direct listing process without a traditional underwritten offering, relying on a financial advisor for price validation and market readiness. No underwriters are involved, and the company will not receive proceeds from secondary sales but may benefit from warrant exercises.

S-1/A amended

Conexeu Sciences Inc. is registering 9,481,123 shares of common stock for resale by registered security holders, including shares from debt settlements, private placements, and crowdfunding offerings. The filing outlines the company's plan to list on Nasdaq under symbol 'CNXU' and details the resale process, including the role of a financial advisor in setting the initial price via Nasdaq's Current Reference Price mechanism. The company emphasizes that it will not receive proceeds from share sales but may benefit from warrant exercises.

S-1/A amended

Conexeu Sciences Inc. is seeking to register the resale of up to 9,481,123 shares of common stock by selling securityholders, including shares from a debt settlement, private placements, business advisory agreements, and Regulation Crowdfunding. The company, an early-stage medical device firm focused on collagen-based regenerative tissue products, is not currently listed on any exchange and seeks Nasdaq Capital Market listing. The offering price ranges from $8.00 to $12.00 per share, with proceeds from warrant exercises potentially benefiting the company.

S-1 filed

Conexeu Sciences Inc. is a biotechnology company focused on developing collagen-based regenerative tissue products. The company, incorporated in Nevada, is offering up to 9,083,334 shares of common stock through selling shareholders, including shares from debt settlements, private placements, and warrants. The filing outlines the resale of these shares without the company receiving proceeds from the resale, though it may benefit from warrant exercises. The company's platform includes a patented collagen scaffold designed for tissue regeneration, targeting markets in aesthetics, wound care, and regenerative medicine. The securities involve high risk, and the company's stock is not currently listed on any exchange.